×

AstraZeneca's Enhertu Receives Fourth US Breakthrough Therapy Designation

Published Oct 04 2021 at 7:54 AM GMT
Key
Points
  • (RTTNews) - AstraZeneca Plc (AZN), on Monday, announced that its cancer drug Enhertu has been granted Breakthrough Therapy Designation by the FDA for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received one or more prior anti-HER2-based regimens.
  • This marks the fourth Breakthrough Therapy.




Trending

Stats

  • Published Oct 4, 2021 7:54 AM GMT